beta cell regeneration modulators (NGM Biopharmaceuticals/Daiichi Sankyo)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug Namebeta cell regeneration modulators (NGM Biopharmaceuticals/Daiichi Sankyo)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRegenerating islet-derived protein 3-alpha modulators
TargetsRegenerating islet-derived protein 3-alpha
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDaiichi Sankyo Co Ltd +[2] 
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A